202 related articles for article (PubMed ID: 28667408)
1. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H; Kanda M; Morita S; Taguri M; Nishikawa K; Shimada M; Muguruma K; Koeda K; Takahashi M; Nakamori M; Konno H; Tsuji A; Hosoya Y; Shirasaka T; Yamamitsu S; Sowa M; Kitajima M; Okajima M; Kobayashi M; Sakamoto J; Saji S; Hirakawa K
Int J Clin Oncol; 2017 Dec; 22(6):1052-1059. PubMed ID: 28667408
[TBL] [Abstract][Full Text] [Related]
2. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
[TBL] [Abstract][Full Text] [Related]
6. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
8. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Sakuma K; Hosoya Y; Arai W; Haruta H; Ui T; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Hyodo M; Nagai H; Yasuda Y; Shirasaka T
Int J Clin Oncol; 2010 Apr; 15(2):166-71. PubMed ID: 20195683
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Koizumi W; Kurihara M; Nakano S; Hasegawa K
Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Br J Cancer; 2007 Aug; 97(4):458-63. PubMed ID: 17653073
[TBL] [Abstract][Full Text] [Related]
16. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
[TBL] [Abstract][Full Text] [Related]
18. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
20. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
